CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 21-821

CHEMISTRY REVIEW(S)





NDA 21-821

Tygacil (tigecycline) for injection

Wyeth Pharmaceuticals

Shrikant N. Pagay Anti-Infective Drug Products

NDA 21-821 Tigacyl (tigecycline) for Injection





Table of Contents

Table of Contents 2
Chemistry Review Data Sheet 5
The Executive Summary9
I. Recommendations9
A. Recommendation and Conclusion on Approvability9
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable9
II. Summary of Chemistry Assessments9
A. Description of the Drug Product(s) and Drug Substance(s)9
B. Description of How the Drug Product is Intended to be Used
C. Basis for Approvability or Not-Approval Recommendation11
III. Administrative11
A. Reviewer's Signature11
B. Endorsement Block11
C. CC Block
Chemistry Assessment12
I. DRUG SUBSTANCE12
1. Description & Characterization12
a. Description
b. Characterization / Proof Of Structure
2. Manufacturer13
3. Synthesis / Method Of Manufacture14
a. Starting Materials - Specs & Tests14
b. Solvents, Reagents, etc
NDA 21-821 Tigacyl





c. Flow Chart17
d. Detailed Description17
4. Process Controls
a. Reaction Completion / Other In-Process Tests
b. Intermediate Specs & Tests
5. Reference Standard
a. Preparation
b. Specifications
6. Regulatory Specifications / Analytical Methods23
a. Drug Substance Specifications & Tests
b. Purity Profile Error! Bookmark not defined.
c. Microbiology
7. Container/Closure System For Drug Substance Storage
8. Drug Substance Stability35
II. DRUG PRODUCT
1. Components/Composition42
2. Specifications & Methods For Drug Product Ingredients
a. Active Ingredient(s)
b. Inactive Ingredients
3. Manufacturer
4. Methods Of Manufacturing And Packaging Error! Bookmark not defined.
a. Production Operations
b. In-Process Controls & Tests Error! Bookmark not defined.
c. Reprocessing Operations
5. Regulatory Specifications And Methods For Drug Product
a. Sampling Procedures
b. Regulatory Specifications And Methods
6. Container/Closure SystemError! Bookmark not defined.
7. Microbiology58
8. Drug Product Stability58
III. INVESTIGATIONAL FORMULATIONS
NDA 21-821
Tigacyl (tigecycline) for Injection

COER

CHEMISTRY REVIEW



IV.EN	NVIRONMENTAL ASSESSMENT	. 46
V. M	ETHODS VALIDATION	.72
VI.LA	ABELING	.72
VII.	ESTABLISHMENT INSPECTION	.73
VIII.	DRAFT DEFICIENCY LETTER	.74





Chemistry Review Data Sheet

Chemistry Review Data Sheet

- 1. NDA 21-821
- 2. REVIEW #: 1
- 3. REVIEW DATE: 2/11/05
- 4. REVIEWER: Shrikant N. Pagay

5. PREVIOUS DOCUMENTS:

Previous Documents

None

Document Date

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed	Document Date
Original	9/27/04
Amendment (stability update)	3/10/2005
Amendment (Response to deficiency comments)	3/18/05
Amendment (Response to deficiency comments)	5/4/05
Correspondence (Response to deficiency comments)	5/27/05
Amendment (Response to label comments) Amendment (update)	6/2/05 6/13/05

7. NAME & ADDRESS OF APPLICANT:

Name: Wyeth Pharmaceuticals

Address: P. O. Box 8299, Philadelphia, PA 19101-8299

Representative:

Mr. Norris Pyle

(484)-865-3218

Telephone:





Chemistry Review Data Sheet

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Tygacil
- b) Non-Proprietary Name (USAN): Tigecycline
- c) Code Name/# (ONDC only): GAR-936; WAY 156936
- d) Chem. Type/Submission Priority (ONDC only):
 - Chem. Type: 1
 - Submission Priority: P
 - •
- 9. LEGAL BASIS FOR SUBMISSION: 505 (b)
- 10. PHARMACOL. CATEGORY: Anti-infective
- 11. DOSAGE FORM: Injectable (lyophilized powder)
- 12. STRENGTH/POTENCY: 50 mg/vial
- 13. ROUTE OF ADMINISTRATION: Injectable
- 14. Rx/OTC DISPENSED: _X_Rx __OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> _____SPOTS product – Form Completed

X Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:


Empirical Formula: C₂₉H₃₀N₅O₈
Molecular Weight: 585.66
Chemical Name: [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethyl)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.

Laboratory Codes: Tigecycline; GAR-936; WAY-156936; RS 738-6; 898595C.





Chemistry Review Data Sheet



17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
(b) (4)	III	(b) (4)	(b) (4)	3	Adequate	5/12/2004	
_	III	(b) (4)	(b) (4)	3	Adequate	5/24/2004	

- ¹ Action codes for DMF Table:
- 1 DMF Reviewed.
- Other codes indicate why the DMF was not reviewed, as follows:
- 2-Type 1 DMF
- 3 Reviewed previously and no revision since last review
- 4 Sufficient information in application
- 5 Authority to reference not granted
- 6 DMF not available
- 7 Other (explain under "Comments")

 2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)





Chemistry Review Data Sheet

B. Other Documents: NA

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	56,518	Original & Amendments

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	NA		
EES	Acceptable	3/8/05	Office Of Compliance
Pharm/Tox	NA		
Biopharm	NA		
LNC	Acceptable	5/16/05	Consult
Methods Validation	Satisfactory	5/2/2005	Consult - OPS Laboratory
OPDRA	Acceptable	3/18/05	Consult
EA	Acceptable	6/14/05	CMC Review
Microbiology	Satisfactory	3/23/05	Bryan Riley- consult

19. COMMENTS:

Please note that all italicized portion of Chemistry Assessment Section are reviewer's comments. The remaining information (data, figures and some responses to deficiencies) is directly incorporated from the submission. This does not apply to the Chemistry Review Data Sheet and the Executive Summary Sections.

Regulatory specifications, i.e., specifications agreed upon CMC review, EER, expiration date of the drug substance and shelf life of the drug product, stability study commitments are listed in the Appendix section for quick reference.





Executive Summary Section

The Chemistry Review for NDA 021-821

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Recommendation to approve NDA 21-821 from CMC consideration.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

NA

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drug Substance

Tigecycline is a tertiary-butyl glycyl substituted analogue of minocycline. Both tigecycline and minocycline are semi-synthetic tetracycline class of drugs. The chemical structure qualifies it as an new molecular entity. It is a broad spectrum antibiotic. The drug substance is an orange colored odorless powder and melts at ^{(b) (4)} Tigecycline is

proposed drug	substance	(b) (4)	However, the
ľ	The synthesis for tigecycline is a	a	(b) (4)

The drug is the drug is the drug substance is freely soluble to oxidation. However, it is stable as solid when placed in the proposed packaging of the drug is bottles and stored between the drug substance is the drug absorbed through the gastro-intestinal tract. The manufacturer of the drug substance is the





Executive Summary Section

Drug Product

The drug product is a sterile lyophilized powder (50 mg/vial) (0.9%) saline or 5% dextrose as an injectable solution. Tigecy as a tablet or capsule or oral suspension due to poor oral biova	cline could not be developed			
	were necessary to			
manufacture a sterile drug product	^{(b) (4)} . Formulation and			
process development studies were performed to determine the	effects of (b) (4)			
Based on the results of these studies, a stable formulation was	developed that contains			
simply the drug substance,	^{(b) (4)} The product			
is manufactured by	(b) (4)			
lyophilization, filling and packaging into vials. Each of these unit operations				
involves several steps and in-process controls. The process co	*			

operations. A ^{(b) (4)} overage i.e. fill weight of ^{(b) (4)} for the 50 mg per vial was necessary to account for the losses during withdrawal of the 50 mg from each vial. The lyophilized drug powder in a dry state is stable for up to 18 months when stored at 25°C/.60% RH. The drug is further diluted into IV bags immediately upon constitution of the vial. The drug product is manufactured at Wyeth's Carolina, Puerto Rico facility by

B. Description of How the Drug Product is Intended to be Used

The drug product is intended to be used intravenously following infections in complicated skin and skin structure and complicated abdominal infections. Each vial contains 53 mg tigecycline lyophilized powder constituted with 5.3 mL of normal saline or 5% dextrose solution to achieve a final concentration of 10 mg/mL. Thereafter, 5 mL of the reconstituted solution should be immediately withdrawn from the vial and added to a 100 mL IV bag for infusion. For 100 mg dose, transfer 2 reconstituted vials into the IV bag. The maximum concentration of reconstituted solution in the IV bag should not exceed 1 mg/mL. The reconstituted solution should be orange or yellow in color; if it is discolored, e.g., green or black, then, discard the solution. Examine the solution for particulate matter. The reconstituted solution in the IV bag is stable at room temperature for up to 6 hours and in refrigerator for up to 24 hours. The recommended dosage regimen is an initial dose of 100 mg followed by 50 mg every 12 hours. The infusion time is between 30 to 60 minutes.





Executive Summary Section

C. Basis for Approvability or Not-Approval Recommendation

Critical CMC Considerations for the Approval of NDA 21-821

Both the drug substance and drug product are well characterized. The manufacturing processes are well established. The shelf life for both the drug substance and the drug product are based on sufficient stability data for batches stored under long term storage conditions. The in-process and final drug substance and drug product specifications are set with full justification.

III. Administrative

A. Reviewer's Signature

B. Endorsement Block

ChemistName/Date: Shrikant N. Pagay ChemistryTeamLeader Name/Date: James Vidra Project Manager Name/Date: Judit Milstein

C. CC Block

75 Pages Have Been Withheld In Full as b4 (CCI/TS) Immediately Following This Page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/ Shrikant Pagay 6/15/05 10:52:53 AM CHEMIST

Jim Vidra 6/15/05 11:14:31 AM CHEMIST

Norman Schmuff 6/15/05 11:25:25 AM CHEMIST